Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

Total Costs & Expenses

$39.93M

TTM · Period ending: Jun 30, 2026 · USD

LCTX Total Costs & Expenses

Latest reported$39.93Mperiod endingJun 30, 2026

Latest reported$39.93Mperiod endingJun 30, 2026

LCTX Total Costs & Expenses ($800.00K → $39.93M)

Annual Total Costs & Expenses

High-resolution chart · PNG

LCTX total costs & expenses history

Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock Total Costs & Expenses — Annual fiscal periods (USD)
Period ending	Total Costs & Expenses (USD)
Dec 31, 2025	36,335,000
Dec 31, 2024	30,977,000
Dec 31, 2023	33,678,000
Dec 31, 2022	37,223,000
Dec 31, 2021	53,107,000
Dec 31, 2020	27,220,000
Dec 31, 2019	40,354,000
Dec 31, 2018	42,411,000
Dec 31, 2017	42,448,000
Dec 31, 2016	61,219,000
Dec 31, 2015	68,343,000
Dec 31, 2014	52,628,946
Dec 31, 2013	41,387,427
Dec 31, 2012	26,693,546
Dec 31, 2011	23,041,193
Dec 31, 2010	13,532,433
Dec 31, 2009	5,445,434
Dec 31, 2008	4,326,424
Dec 31, 2007	2,268,494
Dec 31, 2006	2,913,879
Dec 31, 2005	2,921,611
Dec 31, 2004	2,657,151
Dec 31, 2003	2,246,250
Dec 31, 2002	2,421,649
Dec 31, 2001	3,646,510
Dec 31, 2000	5,142,772
Dec 31, 1999	6,797,211
Dec 31, 1998	2,400,000
Jun 30, 1998	3,300,000
Jun 30, 1996	2,100,000
Jun 30, 1995	2,600,000
Jun 30, 1994	1,700,000
Jun 30, 1993	1,400,000
Jun 30, 1992	800,000

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.